The share sale

Bure Equity AB (publ), (“Bure”) has divested 3,700,000 shares in Mycronic AB (publ) (“Mycronic”). The shares were sold to a price of SEK 235 per share, corresponding to a total sell down of approximately SEK 870 million. Following the share sale, Bure owns 22,617,163 shares in Mycronic corresponding to 23.1 per cent of the total number of outstanding shares and votes.

Bure has entered a lock-up undertaking, with customary exceptions, for a period of 180 days from 7 November 2023.

Carnegie Investment Bank AB (publ) (“Carnegie”) and SEB Corporate Finance, Skandinaviska Enskilda Banken AB (“SEB”) act as joint bookrunners and KANTER Advokatbyrå act as legal advisor in the share sale.

Background

Today, Mycronic is the largest holding for Bure, representing approximately 43 per cent of the net asset value. To increase flexibility and maneuver room for Bure's management and in future investment opportunities, Bure has decided to divest 3.8 per cent of the total number of outstanding shares in Mycronic.

The share sale represents only a minor portion of Bure’s holdings in Mycronic. The decision to only divest a small portion of Bure’s holdings stands as a testament to Bure’s support and commitment as Bure persist in retaining a significant interest in Mycronic’s trajectory.

For more information, contact:

Henrik Blomquist, CEO henrik.blomquist@bure.se
Telephone: +46 (0)70 824 44 74

EU Market Abuse Regulation

This information is such information as Bure Equity AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 19:[●] CET on 7 November 2023.

Important information

Publication, distribution or release of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy any securities in Mycronic in any jurisdiction, neither from Bure nor from anyone else.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the shares. Any investment decision in connection with the Share Sale must be made on the basis of all publicly available information relating to Mycronic and Mycronic’s shares. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This press release does not constitute a recommendation concerning any investor’s option with respect to the Share Sale. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information. The price and value of securities can go down as well as up. Past performance is not a guide to future performance.

This press release does not constitute or form part of an offer or solicitation to purchase securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be published, distributed or released, directly or indirectly, in whole or in part, within or into the United States of America, Australia, Canada, Hong Kong, Israel, Japan, New Zeeland, South Africa, Switzerland or in any other jurisdiction where such publication, distribution or release of the information would not comply with applicable laws and regulations or would require prospectuses, registration or any other measures than those required by Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation 2017/1129 of the European parliament and of the council (the “Prospectus Regulation”) or, with respect to the United Kingdom, the Prospectus Regulation as it forms part of the United Kingdom’s domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”), and has not been approved by any regulatory authority in any jurisdiction. Bure has not authorised any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Share Sale. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

This press release is only being distributed to and is only directed at persons in the United Kingdom that are “qualified investors” within the meaning of the UK Prospectus Regulation who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order or (iii) persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000, as amended,) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). This press release must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this press release must satisfy themselves that it is lawful to do so.

This press release does not constitute a recommendation concerning any investor’s option with respect to the Share Sale. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this press release and publicly available information. The price and value of securities can go down as well as up. Past performance is not a guide to future performance.

This press release may contain forward-looking statements which reflect Bure’s current view on future events and financial and operational development. Words such as “intend”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. Bure does not undertake any obligation to review, update, confirm or release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.